Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors

BMC Infectious Diseases

Table 3 The comparison of prevalence of 8 comorbidities between included COVID-19 patients and the Chinese population [48,49,50,51,52,53]

Disease	Prevalence from Meta-analysis (%)	Prevalence from the general population (%)	P-value ^***	Reference ^a
Hypertension	19	23.2	< 0.001	2018 [48]
Cardiovascular disease	6	1.8	< 0.001	2018 [48]
Cerebrovascular disease	2	0.9	< 0.001	2018 [48]
Diabetes	9	10.9	< 0.001	2013 [50]
COPD	3	8.6	< 0.001	2018 [51]
Chronic liver disease	3	> 24.8	< 0.001	2019 [52]
Chronic kidney disease	2	9.5	< 0.001	2017 [53]
Malignancy	1	0.6	< 0.001	Recent 5-year [49]

*** P < 0.001 The significant difference between the two groups is indicated by the u-test
^aaReferences for the incidence of the indicated diseases in the general population were included in parenthesis. Dates under the heading of Reference refer to the year in which statistic data was collected before

ISSN: 1471-2334